



ELCC 2017 INDUSTRY SATELLITE SYMPOSIUM

Managing Hyponatraemia in Lung Cancer

Expert Consensus Recommendations

This meeting is organised and funded by Otsuka Pharmaceutical Europe Ltd.

Sunday, 7th May 2017

Palexpo, Geneva, 18:40 – 19:40, Room A

Dear Colleagues,

Our symposium **"Managing Hyponatraemia in Lung Cancer Expert Consensus Recommendations"** will consider the wider value of hyponatraemia and SIADH management in lung cancer and the impact that can be made in effective treatment. SIADH and hyponatraemia in lung cancer patients, if not diagnosed and treated, may negatively impact outcomes.

Professor Rossana Berardi and Professor Marcus Säemann, aim to discuss the need of these lung cancer patients and review the most recent data publications on targeted therapies. Alongside sharing personal experiences in their clinics, the esteemed faculty will look at how best to identify these patients, with the aim to challenge current treatment practice.

Finally, they will look at how to help improve patient treatment, improve patient outcomes and provide a combined recommendation on how to manage hyponatraemia in lung cancer.

Throughout the symposium, audience interaction, participation and questions are encouraged.

We look forward to welcoming you to the symposium.

Otsuka Pharmaceutical Europe Ltd

Programme

- 18:40** Welcome and introduction
Professor Rossana Berardi, Italy
- 18:45** Hyponatraemia in the oncology patient
Professor Rossana Berardi
- 19:00** Management, diagnosis and treatment of the oncology patient with hyponatraemia
Professor Marcus Säemann, Austria
- 19:15** Clinical scenarios – an interactive session
Professor Rossana Berardi,
Professor Marcus Säemann
- 19:35** Questions, summary and meeting close
Professor Rossana Berardi

© Otsuka Pharmaceutical Europe Ltd.
Date of Preparation: March 2017 Job Code: OPEL/0117/SAM/1003I(1)
Otsuka Pharmaceutical Europe Ltd., Gallions, Wexham Springs,
Framewood Road, Wexham, SL3 6PJ, UK.

